Long-Term Retention Rate of Anakinra in Adult Onset Still's Disease and Predictive Factors for Treatment Response

scientific article published on 02 April 2019

Long-Term Retention Rate of Anakinra in Adult Onset Still's Disease and Predictive Factors for Treatment Response is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.3389/FPHAR.2019.00296
P932PMC publication ID6454864
P698PubMed publication ID31001115

P50authorLuca CantariniQ30505846
Matteo PigaQ37829183
Giuseppe LopalcoQ38544880
Florenzo IannoneQ38544900
Elena BartoloniQ54060870
Gianfranco VitielloQ55089386
Paolo SfrisoQ58328239
Lorenzo DagnaQ60309835
Giacomo EmmiQ61086244
Serena ColafrancescoQ61146517
Angela TincaniQ73304219
Giovanni LapadulaQ38544910
Maurizio RossiniQ41067734
Giulio CavalliQ42209239
Paola CiprianiQ42416415
Roberto GiacomelliQ42416418
Raffaele MannaQ44815277
Carlomaurizio MontecuccoQ47265945
Elisa GremeseQ50166371
Roberto GerliQ73737873
G ValesiniQ85230265
Roberta PrioriQ87167983
Donato RiganteQ87442620
Elena C CavallaroQ87888765
Piero RuscittiQ88511212
Daniele CammelliQ89890433
Marta MoscaQ90560735
Ilaria PiazzaQ91329276
Paola GalozziQ91923448
Jurgen SotaQ92131554
Rosaria TalaricoQ94547617
Carla GaggianoQ98649610
Maria Grazia MassaroQ99400905
Elena SilvestriQ113819135
Salvatore De VitaQ114291040
Elena BaldisseraQ114314178
Giovanni CanestrariQ114314179
Ginevra De MarchiQ114314182
Micol FrassiQ114314183
Alessandro MathieuQ114314184
Irene PontikakiQ114314185
Micol RomanoQ114314186
Chiara StagnaroQ114314187
Ombretta ViapianaQ114314188
Lorenza Maria ArgoliniQ114417395
P2093author name stringSilvia Rossi
Gianfranco Ferraccioli
Antonio Vitale
P2860cites workLife-threatening complications of adult-onset Still's diseaseQ33412732
"Adolescent-onset Still's disease": characteristics and outcome in comparison with adult-onset Still's diseaseQ34137374
Adult-onset Still's disease. Clinical course and outcomeQ34191960
Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still's disease. An open, randomized, multicenter studyQ34292030
Preliminary criteria for classification of adult Still's diseaseQ34405573
The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritisQ34774277
Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide surveyQ35122583
Is Still's Disease an Autoinflammatory Syndrome?Q35955190
Biological treatment in systemic juvenile idiopathic arthritis: achievement of inactive disease or clinical remission on a first, second or third biological agentQ36183846
Efficacy of Anakinra in Refractory Adult-Onset Still's Disease: Multicenter Study of 41 Patients and Literature Review.Q36195807
Adult-onset Still's disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centersQ36208563
Adult Still's disease: manifestations, disease course, and outcome in 62 patientsQ37670649
Cutaneous manifestations associated with adult-onset Still's disease: important diagnostic valuesQ37971317
Systemic juvenile idiopathic arthritisQ38033873
Cutaneous manifestations of adult-onset Still's disease: a case report and review of literatureQ38204937
Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study.Q51740150
Serum Levels of Interleukin 33 and Soluble ST2 Are Associated with the Extent of Disease Activity and Cutaneous Manifestations in Patients with Active Adult-onset Still's Disease.Q52884955
Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still's disease.Q54695048
Bridging the gap between the clinician and the patient with cryopyrin-associated periodic syndromesQ58326254
Anakinra in Systemic Juvenile Idiopathic Arthritis: A Single-center ExperienceQ61911597
Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Still's Disease: A Multicentre Retrospective Observational StudyQ38703626
A systematic approach to autoinflammatory syndromes: a spelling booklet for the beginnerQ38773387
H-ferritin and CD68(+) /H-ferritin(+) monocytes/macrophages are increased in the skin of adult-onset Still's disease patients and correlate with the multi-visceral involvement of the disease.Q39673488
Persistent pruritic papules and plaques associated with adult-onset Still's disease: report of six casesQ40214423
Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter seriesQ40335671
Clinical features and prognosis in adult-onset Still's disease: a study of 104 casesQ40356429
Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in FranceQ40436579
Efficacy and safety of biological agents in adult-onset Still's disease.Q41472240
A case of refractory adult-onset Still's disease treated with anakinraQ42939560
Persistent pruritic papules and plaques: a characteristic histopathologic presentation seen in a subset of patients with adult-onset and juvenile Still's diseaseQ43025256
Adult onset Still's disease with persistent skin lesions complicated by secondary hemophagocytic lymphohistiocytosisQ43563929
Anakinra in adult-onset Still's disease: long-term treatment in patients resistant to conventional therapyQ44201170
Adult onset Still's disease in northern India: comparison with juvenile onset Still's diseaseQ44602919
Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC RegisterQ47580938
Proposal for a new set of classification criteria for adult-onset still diseaseQ78069999
Is Still's disease an autoinflammatory syndrome?Q82976137
Evanescent and persistent pruritic eruptions of adult-onset still disease: a clinical and pathologic study of 36 patientsQ84420763
Clinical manifestations but not cytokine profiles differentiate adult-onset Still's disease and sepsisQ84973391
P275copyright licenseCreative Commons Attribution 4.0 InternationalQ20007257
P6216copyright statuscopyrightedQ50423863
P407language of work or nameEnglishQ1860
P921main subjectanakinraQ415411
Still's diseaseQ3281303
P304page(s)296
P577publication date2019-04-02
P1433published inFrontiers in PharmacologyQ2681208
P1476titleLong-Term Retention Rate of Anakinra in Adult Onset Still's Disease and Predictive Factors for Treatment Response
P478volume10

Reverse relations

cites work (P2860)
Q90049900Anakinra Drug Retention Rate and Predictive Factors of Long-Term Response in Systemic Juvenile Idiopathic Arthritis and Adult Onset Still Disease
Q90182004Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Still's Disease and Effect on Clinical and Laboratory Outcomes
Q89665968Editorial: New Therapies in the Field of Rheumatology
Q97653199Pro-inflammatory properties of H-ferritin on human macrophages, ex vivo and in vitro observations

Search more.